Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00060112 · ClinicalTrials.gov registry record · Phase 1
Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00060112: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00060112 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00060112, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
Drugs used in chemotherapy such as gemcitabine use different ways to stop cancer cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of gemcitabine by making cancer cells more sensitive to the drug. This phase I trial is studying the side effects and best dose of oblimersen and gemcitabine in treating patients with metastatic or unresectable solid tumors or lymphoma
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG gemcitabine hydrochloride
- BIOLOGICAL oblimersen sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2003-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00060112
The ClinicalTrials.gov registry entry for NCT00060112 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00060112 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00060112 about?
NCT00060112 is a clinical study titled "Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma". Drugs used in chemotherapy such as gemcitabine use different ways to stop cancer cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of gemcitabine by making cancer cells more sensitive to the drug. This phase I trial is studying the side effects and best dose ...
What is the current status of trial NCT00060112?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2003-03.
What interventions are being tested in trial NCT00060112?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), gemcitabine hydrochloride (DRUG), oblimersen sodium (BIOLOGICAL).
Who is sponsoring clinical trial NCT00060112?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.